Amgen Files 2023 Annual Report, Details Fiscal Year End

TL;DR

Amgen just dropped its 2023 annual report, giving us the full financial picture for the year ending December 31st!

AI Summary

AMGEN INC filed its 10-K report on February 14, 2024, for the fiscal year ended December 31, 2023. The filing, identified by CIK 0000318154, details the company's annual financial performance and operational status. While specific dollar amounts for revenue or profit are not provided in this snippet, the document covers key financial areas such as product sales for 2023, 2022, and 2021, common stock, and senior notes due in 2026.

Why It Matters

This 10-K filing provides a comprehensive overview of Amgen's financial health and operations for the past year, crucial for investors and analysts to assess its performance and future prospects.

Risk Assessment

Risk Level: medium — A 10-K filing is a standard regulatory disclosure; the risk level depends on the detailed financial and operational information within the full document, which is not fully provided here.

Key Numbers

• 2023-12-31 — Fiscal Year End (The period covered by this annual report.)
• 2024-02-14 — Filing Date (The date the 10-K was officially filed with the SEC.)
• 0000318154 — CIK (Unique identifier for AMGEN INC with the SEC.)
• 2836 — SIC Code (Standard Industrial Classification for Biological Products (No Diagnostic Substances).)

Key Players & Entities

• AMGEN INC (company) — filer of the 10-K
• 0000318154 (company) — Central Index Key (CIK) for AMGEN INC
• 20231231 (date) — Conformed Period of Report
• 20240214 (date) — Filed As Of Date
• ONE AMGEN CENTER DRIVE (address) — Business Address Street 1
• THOUSAND OAKS (address) — Business Address City
• CA (address) — Business Address State
• 91320 (address) — Business Address Zip
• (805)447-1000 (phone_number) — Business Phone
• DE (state) — State of Incorporation

FAQ

From the Filing

0000318154-24-000011.txt : 20240214 0000318154-24-000011.hdr.sgml : 20240214 20240214162332 ACCESSION NUMBER: 0000318154-24-000011 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 172 CONFORMED PERIOD OF REPORT: 20231231 FILED AS OF DATE: 20240214 DATE AS OF CHANGE: 20240214 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMGEN INC CENTRAL INDEX KEY: 0000318154 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 953540776 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-37702 FILM NUMBER: 24638830 BUSINESS ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 BUSINESS PHONE: (805)447-1000 MAIL ADDRESS: STREET 1: ONE AMGEN CENTER DRIVE CITY: THOUSAND OAKS STATE: CA ZIP: 91320 FORMER COMPANY: FORMER CONFORMED NAME: AMGEN DATE OF NAME CHANGE: 19870305 10-K 1 amgn-20231231.htm 10-K amgn-20231231 0000318154 false 2023 FY http://fasb.org/srt/2023#PartnershipInterestMember http://fasb.org/srt/2023#PartnershipInterestMember http://fasb.org/us-gaap/2023#OtherGeneralExpense http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#OtherAssetsNoncurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#AccruedLiabilitiesCurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent http://fasb.org/us-gaap/2023#OtherLiabilitiesNoncurrent 0000318154 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000318154 amgn:A2.00SeniorNotesDue2026Member 2023-01-01 2023-12-31 0000318154 2023-06-30 iso4217:USD 0000318154 2024-02-09 xbrli:shares 0000318154 2023-10-01 2023-12-31 0000318154 us-gaap:ProductMember 2023-01-01 2023-12-31 0000318154 us-gaap:ProductMember 2022-01-01 2022-12-31 0000318154 us-gaap:ProductMember 2021-01-01 2021-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2023-01-01 2023-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2022-01-01 2022-12-31 0000318154 us-gaap:ProductAndServiceOtherMember 2021-01-01 2021-12-31 0000318154 2022-01-01 2022-12-31 0000318154 2021-01-01 2021-12-31 iso4217:USD xbrli:shares 0000318154 2023-12-31 0000318154 2022-12-31 0000318154 us-gaap:CommonStockMember 2020-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2020-12-31 0000318154 us-gaap:RetainedEarningsMember 2020-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-12-31 0000318154 2020-12-31 0000318154 us-gaap:RetainedEarningsMember 2021-01-01 2021-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-01-01 2021-12-31 0000318154 us-gaap:CommonStockMember 2021-01-01 2021-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-01-01 2021-12-31 0000318154 us-gaap:CommonStockMember 2021-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2021-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0000318154 2021-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-01-01 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-01-01 2022-12-31 0000318154 us-gaap:CommonStockMember 2022-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2022-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0000318154 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0000318154 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockIncludingAdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0000318154 us-gaap:CommonStockMember 2023-1